Email ID
Password
Scrip   
US FDA accepts Flutiform NDA
22 May 2009
Alex Shimmings

SkyePharma is one step closer to US approval for its lead development product, the combination asthma therapy Flutiform (fluticasone propionate plus formoterol fumarate).

The product has been accepted for filing by the FDA for the treatment of persistent asthma in patients aged 12 years...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36